Inspyr Therapeutics, Inc. (1421204) SEC Filing 8-K Material Event for the period ending Monday, September 30, 2019

Inspyr Therapeutics, Inc.

CIK: 1421204

View differences made from one to another to evaluate Inspyr Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inspyr Therapeutics, Inc..


Assess how Inspyr Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inspyr Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Inspyr Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

CIK: 1421204
Form Type: 8-K Corporate News
Accession Number: 0001213900-19-019331
Submitted to the SEC: Mon Sep 30 2019 4:39:53 PM EST
Accepted by the SEC: Mon Sep 30 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations
  1. Bylaw Change
  2. Financial Exhibit

External Resources:

Bookmark the Permalink: